| Name | SNDX-5613 |
| Description | Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement. |
| In vitro | METHODS: Primary patient-derived NUP98-r AML cells were treated with Revumenib (SNDX-5613) (2, 46, 125 nM) and cell viability was measured.
RESULTS Revumenib inhibited the growth of primary patient-derived NUP98-r AML cells. [3] |
| In vivo | SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.SNDX-5613 shows in vivo plasma( IC50 : 53 nM) . |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (95.11 mM), Sonication is recommended.
|
| Keywords | SNDX-5613 | SNDX5613 | SNDX 5613 | myeloid | MLL | Menin-MLL | Menin | lymphoblastic | Leukemia | Inhibitor | inhibit | HistoneMethyltransferase | Histone Methyltransferase | EpigeneticReaderDomain | Epigenetic Reader Domain | AML | ALL | acute |
| Inhibitors Related | MAK-683 hydrochloride | ABBV-744 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | Tazemetostat | Piribedil | Curcumin | EPZ015666 | iso-Azalansta | Naphthol AS-E | MRTX-1719 | Bisdemethoxycurcumin |
| Related Compound Libraries | Methylation Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |